利用红外成像观察多发性骨髓瘤患者中与抗体药物结合剂贝兰他单抗马福多汀相关的角膜病变

IF 1.9 3区 医学 Q2 OPHTHALMOLOGY
Cornea Pub Date : 2025-02-01 Epub Date: 2024-06-18 DOI:10.1097/ICO.0000000000003596
Vivian Gallin, Bernhard Nölle, Natalie Schub, Johann Roider
{"title":"利用红外成像观察多发性骨髓瘤患者中与抗体药物结合剂贝兰他单抗马福多汀相关的角膜病变","authors":"Vivian Gallin, Bernhard Nölle, Natalie Schub, Johann Roider","doi":"10.1097/ICO.0000000000003596","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>The treatment of patients with relapsed/refractory multiple myeloma (RRMM) with the antibody-drug conjugate belantamab mafodotin is affected by ocular adverse effects, most frequently keratopathy with corneal microcyst-like epithelial changes (MECs). To assess ocular side effects, the Keratopathy and Visual Acuity (KVA) scale, based on the extent of keratopathy subjectively graded on slit-lamp examination and the change in best corrected visual acuity from baseline, was created. Advanced corneal imaging techniques have been explored to further characterize MECs and identify objective imaging biomarkers. We examined whether infrared reflectance imaging of the anterior segment (AS-IR) could contribute to the assessment, monitoring, and documentation of corneal toxicity in patients treated with belantamab mafodotin.</p><p><strong>Methods: </strong>In addition to the KVA examination, AS-IR imaging was performed. AS-IR images were evaluated for presence of visible hyporeflective lesions and their spatial and temporal distribution between visits and compared with keratopathy identified on slit-lamp examination. To standardize the assessment, a scoring system for lesions on AS-IR was implemented for additional analysis.</p><p><strong>Results: </strong>Nine patients undergoing treatment with belantamab mafodotin for up to 9 months were examined. All patients exhibited hyporeflective lesions on AS-IR imaging, indicative of corneal toxicity corresponding to MECs observed on slit-lamp examination. AS-IR lesions showed early occurrence, variable quantity and size, and distinct distribution patterns, correlating with clinical findings during treatment.</p><p><strong>Conclusions: </strong>As shown for belantamab mafodotin, AS-IR imaging represents a fast, noninvasive, supplemental method for documentation, monitoring, and assessment of corneal adverse effects during treatment with antibody-drug conjugates, which may enable more standardized analyses.</p>","PeriodicalId":10710,"journal":{"name":"Cornea","volume":" ","pages":"196-202"},"PeriodicalIF":1.9000,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11676612/pdf/","citationCount":"0","resultStr":"{\"title\":\"Visualization of Keratopathy Associated With the Antibody-Drug Conjugate Belantamab Mafodotin Using Infrared Imaging in Patients With Multiple Myeloma.\",\"authors\":\"Vivian Gallin, Bernhard Nölle, Natalie Schub, Johann Roider\",\"doi\":\"10.1097/ICO.0000000000003596\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Purpose: </strong>The treatment of patients with relapsed/refractory multiple myeloma (RRMM) with the antibody-drug conjugate belantamab mafodotin is affected by ocular adverse effects, most frequently keratopathy with corneal microcyst-like epithelial changes (MECs). To assess ocular side effects, the Keratopathy and Visual Acuity (KVA) scale, based on the extent of keratopathy subjectively graded on slit-lamp examination and the change in best corrected visual acuity from baseline, was created. Advanced corneal imaging techniques have been explored to further characterize MECs and identify objective imaging biomarkers. We examined whether infrared reflectance imaging of the anterior segment (AS-IR) could contribute to the assessment, monitoring, and documentation of corneal toxicity in patients treated with belantamab mafodotin.</p><p><strong>Methods: </strong>In addition to the KVA examination, AS-IR imaging was performed. AS-IR images were evaluated for presence of visible hyporeflective lesions and their spatial and temporal distribution between visits and compared with keratopathy identified on slit-lamp examination. To standardize the assessment, a scoring system for lesions on AS-IR was implemented for additional analysis.</p><p><strong>Results: </strong>Nine patients undergoing treatment with belantamab mafodotin for up to 9 months were examined. All patients exhibited hyporeflective lesions on AS-IR imaging, indicative of corneal toxicity corresponding to MECs observed on slit-lamp examination. AS-IR lesions showed early occurrence, variable quantity and size, and distinct distribution patterns, correlating with clinical findings during treatment.</p><p><strong>Conclusions: </strong>As shown for belantamab mafodotin, AS-IR imaging represents a fast, noninvasive, supplemental method for documentation, monitoring, and assessment of corneal adverse effects during treatment with antibody-drug conjugates, which may enable more standardized analyses.</p>\",\"PeriodicalId\":10710,\"journal\":{\"name\":\"Cornea\",\"volume\":\" \",\"pages\":\"196-202\"},\"PeriodicalIF\":1.9000,\"publicationDate\":\"2025-02-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11676612/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cornea\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1097/ICO.0000000000003596\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/6/18 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"OPHTHALMOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cornea","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/ICO.0000000000003596","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/6/18 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

目的:对复发性/难治性多发性骨髓瘤(RRMM)患者使用抗体药物共轭物贝仑单抗马福多汀进行治疗时会出现眼部不良反应,其中最常见的是角膜病变和角膜微囊样上皮变化(MECs)。为了评估眼部副作用,根据裂隙灯检查中主观分级的角膜病变程度和最佳矫正视力与基线相比的变化,制定了 "角膜病变和视力(KVA)量表"。为了进一步描述 MECs 的特征并确定客观的成像生物标志物,人们对先进的角膜成像技术进行了探索。我们研究了前段红外反射成像(AS-IR)是否有助于评估、监测和记录接受贝仑单抗马福多汀治疗的患者的角膜毒性:除 KVA 检查外,还进行了 AS-IR 成像检查。方法:除 KVA 检查外,还进行 AS-IR 成像检查,评估是否存在可见的低反射病变及其在就诊期间的空间和时间分布,并与裂隙灯检查发现的角膜病变进行比较。为了使评估标准化,还采用了 AS-IR 病变评分系统进行补充分析:对接受贝仑单抗-马福多汀治疗长达 9 个月的 9 名患者进行了检查。所有患者在 AS-IR 成像上都显示出低反射性病变,这表明角膜毒性与裂隙灯检查中观察到的 MECs 相对应。AS-IR病变出现早,数量和大小不一,分布模式明显,与治疗期间的临床发现相关:正如贝兰他单抗马福多汀所显示的,AS-IR成像是一种快速、无创、补充性的方法,可用于记录、监测和评估抗体药物共轭物治疗期间的角膜不良反应,从而使分析更加标准化。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Visualization of Keratopathy Associated With the Antibody-Drug Conjugate Belantamab Mafodotin Using Infrared Imaging in Patients With Multiple Myeloma.

Purpose: The treatment of patients with relapsed/refractory multiple myeloma (RRMM) with the antibody-drug conjugate belantamab mafodotin is affected by ocular adverse effects, most frequently keratopathy with corneal microcyst-like epithelial changes (MECs). To assess ocular side effects, the Keratopathy and Visual Acuity (KVA) scale, based on the extent of keratopathy subjectively graded on slit-lamp examination and the change in best corrected visual acuity from baseline, was created. Advanced corneal imaging techniques have been explored to further characterize MECs and identify objective imaging biomarkers. We examined whether infrared reflectance imaging of the anterior segment (AS-IR) could contribute to the assessment, monitoring, and documentation of corneal toxicity in patients treated with belantamab mafodotin.

Methods: In addition to the KVA examination, AS-IR imaging was performed. AS-IR images were evaluated for presence of visible hyporeflective lesions and their spatial and temporal distribution between visits and compared with keratopathy identified on slit-lamp examination. To standardize the assessment, a scoring system for lesions on AS-IR was implemented for additional analysis.

Results: Nine patients undergoing treatment with belantamab mafodotin for up to 9 months were examined. All patients exhibited hyporeflective lesions on AS-IR imaging, indicative of corneal toxicity corresponding to MECs observed on slit-lamp examination. AS-IR lesions showed early occurrence, variable quantity and size, and distinct distribution patterns, correlating with clinical findings during treatment.

Conclusions: As shown for belantamab mafodotin, AS-IR imaging represents a fast, noninvasive, supplemental method for documentation, monitoring, and assessment of corneal adverse effects during treatment with antibody-drug conjugates, which may enable more standardized analyses.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Cornea
Cornea 医学-眼科学
CiteScore
5.20
自引率
10.70%
发文量
354
审稿时长
3-6 weeks
期刊介绍: For corneal specialists and for all general ophthalmologists with an interest in this exciting subspecialty, Cornea brings together the latest clinical and basic research on the cornea and the anterior segment of the eye. Each volume is peer-reviewed by Cornea''s board of world-renowned experts and fully indexed in archival format. Your subscription brings you the latest developments in your field and a growing library of valuable professional references. Sponsored by The Cornea Society which was founded as the Castroviejo Cornea Society in 1975.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信